Back to Authors

Poduslo, Joseph F.

Mayo Clinic

Mayo Clinic

Citations 30

Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin
Zhou, Andrew L., Sharda, Nidhi, Sarma, Vidur , Ahlschwede, Kristen M. , Curran, Geoffry L., Poduslo, Joseph F., Lowe, Val J. , Kandimalla, Karunya K. , Kandimalla, Karunya K , Tang, Xiaojia , Kalari, Krishna R.

Journal of Alzheimer's Disease | December 17, 2021 | Volume: 85 | Issue: 3 | Pages: 1031-1044

10.3233/jad-215128 Get It

Background: Age is the most common risk factor for Alzheimer’s disease (AD), a neurodegenerative disorder characterized by the hallmarks of toxic amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles. Moreover, sub-physiological brain insulin levels have emerged as a pathological manifestation of AD. Objective: Identify age-related changes in the plasma disposition and blood-brain barrier (BBB) trafficking of Aβ peptides and insulin in mice. Methods: Upon systemic injection of 125I-Aβ40, 125I-Aβ42, or 125I-insulin, the plasma pharmacokinetics and brain influx were assessed in wild-type (WT) or AD transgenic (APP/PS1) mice at various ages. Additionally, publicly available single-cell RNA-Seq data [GSE129788] was employed to investigate pathways regulating BBB transport in WT mice at different ages. Results: The brain influx of 125I-Aβ40, estimated as the permeability-surface area product, decreased with age, accompanied by an increase in plasma AUC. In contrast, the brain influx of 125I-Aβ42 increased with age, accompanied by a decrease in plasma AUC. The age-dependent changes observed in WT mice were accelerated in APP/PS1 mice. As seen with 125I-Aβ40, the brain influx of 125I-insulin decreased with age in WT mice, accompanied by an increase in plasma AUC. This finding was further supported by dynamic single-photon emission computed tomography (SPECT/CT) imaging studies. RAGE and PI3K/AKT signaling pathways at the BBB, which are implicated in Aβ and insulin transcytosis, respectively, were upregulated with age in WT mice, indicating BBB insulin resistance. Conclusion: Aging differentially affects the plasma pharmacokinetics and brain influx of Aβ isoforms and insulin in a manner that could potentially augment AD risk.
How Neurons Internalize Alzheimer's Disease Amyloid β Protein
Worthy, Patrice N, Olenych, Scott G., Fulzele, Smita, Davidson, Michael W. , Poduslo, Joseph F., Kandimalla, Karunya K.

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.lb258 Get It

Objective The objective is to investigate cellular mechanisms mediating the internalization of beta‐amyloid 40 (Aβ40) in part of the neurovascular unit, neurons, and blood‐brain barrier (BBB) endothelial cells. Methods Localization of fluorescein labeled Aβ40 (F‐Aβ40) and other endocytotic markers in wild type (WT) mouse brain slices, PC12 cells, rat primary hippocampal (RPH) neurons, and bovine brain microvascular endothelial (BBME) cells was investigated using laser confocal or fluorescence microscopy. The uptake of fluorophores in these cells was quantified by flow cytometry. Results Laser confocal micrographs of WT mouse brain slices treated with F‐Aβ40 demonstrated selective accumulation of the protein in cortical and hippocampal neurons via non‐saturable, energy independent, and non‐endocytotic pathways. A significant portion of internalized Aβ40 is located outside of the endosomal or lysosomal compartments, which may accumulate without degradation. In contrast, BBME cells exhibit energy dependent uptake of Aβ40, and accumulate the protein in acidic cell organelles, indicative of endocytotic uptake. Conclusion The difference in internalization of Aβ40 between neurons and BBB endothelial cells may provide clues to understanding how various cells can regulate Alzheimer's disease (AD) proteins and help explain the vulnerability of cortical and hippocampal neurons to AD toxicity.
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain
Swaminathan, Suresh Kumar, Ahlschwede, Kristen M. , Sarma, Vidur , Curran, Geoffry L., Omtri, Rajesh S. , Decklever, Teresa, Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Journal of Cerebral Blood Flow & Metabolism | June 1, 2017 | Volume: 38 | Issue: 5 | Pages: 904-918

10.1177/0271678x17709709 Get It

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood–brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer’s disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
Unique molecular signatures of Alzheimer's disease amyloid β peptide mutations and deletion during aggregate/oligomer/fibril formation
Poduslo, Joseph F., Howell, Kyle G.

Journal of Neuroscience Research | November 13, 2014 | Volume: 93 | Issue: 3 | Pages: 410-423

10.1002/jnr.23507 Get It

The formation of amyloid β (Aβ) peptide aggregates, oligomers, and fibrils is a dynamic process; however, the kinetics of their formation is not well understood. This study compares the time course of aggregate/fibril formation by transmission electron microscopy (TEM) analyses with that of oligomer/fibril formation by Western blot analysis under native and denaturing conditions. Efforts to deaggregate/defibrillate these peptides by using hexafluoroisopropanol, ammonium hydroxide, or dimethylsulfoxide did not change the nondenaturing polyacrylamide gel electrophoresis (PAGE) footprints or drive the peptides to a monomeric species. Regardless of the pretreatment protocol, TEM analyses reveal that all Aβ peptides (Aβ40, Aβ42, Aβ39E22Δ [Osaka], Aβ40E22G [Arctic], Aβ40E22Q [Dutch], and Aβ40A2T [Icelandic]) immediately formed nonfibrillar, amorphous aggregates when first placed into solution with the Osaka mutation, quickly forming early‐stage fibrils. The extent of fibril formation for other Aβ peptides is time dependent, with the Arctic mutation forming fibrils at 1 hr, the Dutch and Icelandic at 4 hr, Aβ42 at 8 hr, and Aβ40 at 24 hr. In contrast, nondenaturing PAGE revealed unique footprints for the different Aβ species. The rapidity of aggregate formation and the rapid transition to fibrils, particularly for the Osaka deletion, suggest an important role for aggregates/fibrils of Aβ in the development of neuronal degeneration. © 2014 Wiley Periodicals, Inc.
O3–07–04: Axonal trafficking inhibition in neurons depends on the aggregation state of Alzheimer's disease beta‐amyloid peptides and their binding to the plasma membrane
Howell, Kyle G., Poduslo, Joseph F., Trushina, Eugenia

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2013.04.276 Get It

Traffic Jam at the Blood–Brain Barrier Promotes Greater Accumulation of Alzheimer’s Disease Amyloid-β Proteins in the Cerebral Vasculature
Agyare, Edward K., Leonard, Sarah R., Curran, Geoffry L., Yu, Caroline C., Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Paravastu, Anant K. , Kandimalla, Karunya K

Molecular Pharmaceutics | December 18, 2012 | Volume: 10 | Issue: 5 | Pages: 1557-1565

10.1021/mp300352c Get It

P3‐048: Alzheimer's disease beta‐amyloid protein mutations and deletions that define neuronal binding/internalization as early‐state nonfibrillar/fibrillar aggregates and late‐state fibrils
Poduslo, Joseph F., Howell, Kyle G., Olson, Nicole, Ramı́rez-Alvarado, Marina

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2012.05.2124 Get It

P2‐077: Early mitochondrial dysfunction in the etiology of Alzheimer's disease
Zhang, Song , Dzeja, Petras P. , Poduslo, Joseph F., Trushina, Eugenia , Nemutlu, Emirhan

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2012.05.781 Get It

Increased endoneurial albumin in diabetic polyneuropathy
Ohi, Takekazu, Poduslo, Joseph F., Dyck, Peter James

Neurology | May 13, 2012 | Volume: 35 | Issue: 12 | Pages: 1790-1790

10.1212/wnl.35.12.1790 Get It

Differences in the Cellular Uptake and Intracellular Itineraries of Amyloid Beta Proteins 40 and 42: Ramifications for the Alzheimer’s Drug Discovery
Omtri, Rajesh S. , Davidson, Michael W. , Arumugam, Balasubramaniam, Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Molecular Pharmaceutics | May 11, 2012 | Volume: 9 | Issue: 7 | Pages: 1887-1897

10.1021/mp200530q Get It